RU2016105310A - Пиперазин-замещенные мостиковые производные спиро[2.4]гептана в качестве агонистов alx рецептора - Google Patents

Пиперазин-замещенные мостиковые производные спиро[2.4]гептана в качестве агонистов alx рецептора Download PDF

Info

Publication number
RU2016105310A
RU2016105310A RU2016105310A RU2016105310A RU2016105310A RU 2016105310 A RU2016105310 A RU 2016105310A RU 2016105310 A RU2016105310 A RU 2016105310A RU 2016105310 A RU2016105310 A RU 2016105310A RU 2016105310 A RU2016105310 A RU 2016105310A
Authority
RU
Russia
Prior art keywords
compound
mediated
formula
disorders
pharmaceutically acceptable
Prior art date
Application number
RU2016105310A
Other languages
English (en)
Inventor
Оливье КОРМЕНБЁФ
Сильвьяне КРЕН
Давиде ПОЗЗИ
Original Assignee
Актелион Фармасьютиклз Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Актелион Фармасьютиклз Лтд filed Critical Актелион Фармасьютиклз Лтд
Publication of RU2016105310A publication Critical patent/RU2016105310A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (8)

1. Соединение формулы (I), где соединение представляет собой (5R)-N5-(1-(n-толил)циклопропил)-(6R)-N6-(2-(4-метилпиперазин-1-ил)этил)-(4S,7R)-[4,7-этилен-спиро[2.4]гептан]-5,6-дикарбоксамид;
Figure 00000001
или соль соединения.
2. Соединение формулы (I) по п. 1, или его фармацевтически приемлемая соль, для применения в качестве лекарственного средства.
3. Фармацевтическая композиция, которая содержит, в качестве активного компонента, соединение формулы (I) по п. 1, или его фармацевтически приемлемую соль, и по меньшей мере один терапевтически инертный наполнитель.
4. Применение соединения формулы (I) по п. 1, или его фармацевтически приемлемой соли, для приготовления лекарственного средства для предотвращения или лечения заболевания, выбранного из воспалительных заболеваний, обструктивных заболеваний дыхательных путей, аллергических состояний, ВИЧ-опосредованных ретровирусных инфекций, сердечно-сосудистых нарушений, нейровоспаления, неврологических нарушений, боли, заболеваний, опосредованных прионами и нарушений, опосредованных амилоидом; и для модуляции иммунных ответов.
5. Соединение формулы (I) по п. 1, или его фармацевтически приемлемая соль, для применения для предотвращения или
лечения заболевания, выбранного из воспалительных заболеваний, обструктивных заболеваний дыхательных путей, аллергических состояний, ВИЧ-опосредованных ретровирусных инфекций, сердечно-сосудистых нарушений, нейровоспаления, неврологических нарушений, боли, заболеваний, опосредованных прионами и нарушений, опосредованных амилоидом; и для модуляции иммунных ответов.
RU2016105310A 2013-07-18 2014-07-17 Пиперазин-замещенные мостиковые производные спиро[2.4]гептана в качестве агонистов alx рецептора RU2016105310A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IB2013055906 2013-07-18
IBPCT/IB2013/055906 2013-07-18
PCT/EP2014/065351 WO2015007830A1 (en) 2013-07-18 2014-07-17 Piperazine substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists

Publications (1)

Publication Number Publication Date
RU2016105310A true RU2016105310A (ru) 2017-08-23

Family

ID=51205401

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016105310A RU2016105310A (ru) 2013-07-18 2014-07-17 Пиперазин-замещенные мостиковые производные спиро[2.4]гептана в качестве агонистов alx рецептора

Country Status (13)

Country Link
US (1) US9533964B2 (ru)
EP (1) EP3022188B1 (ru)
JP (1) JP6330038B2 (ru)
KR (1) KR20160033747A (ru)
CN (1) CN105377824B (ru)
AU (1) AU2014292064B2 (ru)
BR (1) BR112016001106A8 (ru)
CA (1) CA2915757A1 (ru)
ES (1) ES2639798T3 (ru)
MX (1) MX360699B (ru)
RU (1) RU2016105310A (ru)
TW (1) TW201536289A (ru)
WO (1) WO2015007830A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3022188B1 (en) 2013-07-18 2017-06-07 Actelion Pharmaceuticals Ltd Piperazine substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
BR112016025659B1 (pt) 2014-05-13 2023-03-07 Novartis Ag Indutores de condrogênese, seu uso, e composição farmacêutica
ES2791340T3 (es) 2015-05-27 2020-11-03 Kyorin Seiyaku Kk Derivado de urea o sal farmacológicamente aceptable del mismo
CN107849049B (zh) 2015-05-27 2021-03-16 杏林制药株式会社 脲衍生物或其药用盐

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686454A (en) 1993-07-16 1997-11-11 Merck & Co., Inc. Camphorcarbonyl
WO2001057074A1 (en) 2000-02-04 2001-08-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ligands for fpr class receptors that induce a host immune response to a pathogen or inhibit hiv infection
US20050164305A1 (en) 2002-04-03 2005-07-28 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1)
AU2004290368A1 (en) 2003-11-07 2005-05-26 Acadia Pharmaceuticals Inc. Use of the lipoxin receptor, FPRL1, as a tool for identifying compounds effective in the treatment of pain and inflammation
AR069650A1 (es) 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
ATE520689T1 (de) 2007-12-18 2011-09-15 Actelion Pharmaceuticals Ltd Aminotriazolderivate als alx-agonisten
WO2010134014A1 (en) * 2009-05-18 2010-11-25 Actelion Pharmaceuticals Ltd Bridged spiro [2.4] heptane derivatives as alx receptor and/or fprl2 agonists
NZ597453A (en) 2009-06-09 2013-03-28 Actelion Pharmaceuticals Ltd Fluorinated aminotriazole derivatives as alxr agonists
US8674111B2 (en) 2009-06-12 2014-03-18 Actelion Pharmaceuticals Ltd. Oxazole and thiazole derivatives as ALX receptor agonists
EP2585054A1 (en) * 2010-06-24 2013-05-01 Allergan, Inc. Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
ES2553635T3 (es) * 2010-11-17 2015-12-10 Actelion Pharmaceuticals Ltd. Derivados de éster spiro[2.4]heptano puenteados
AR084172A1 (es) 2010-12-07 2013-04-24 Actelion Pharmaceuticals Ltd Derivados aminotriazol hidroxilados como agonistas del receptor alx
AR084173A1 (es) 2010-12-07 2013-04-24 Actelion Pharmaceuticals Ltd Derivados oxazolil-metileter como agonistas del receptor alx
WO2013009543A1 (en) 2011-07-11 2013-01-17 Allergan, Inc. Polycyclic pyrrolidine-2,5-dione derivatives as -formyl peptide receptor like-1 (fprl-1) receptor modulators
MA37618B1 (fr) * 2012-05-16 2017-08-31 Actelion Pharmaceuticals Ltd Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx
CN104284887B (zh) * 2012-05-16 2016-06-22 埃科特莱茵药品有限公司 作为alx受体激动剂的经1-(对-甲苯基)环丙基取代的桥联螺[2.4]庚烷衍生物
CA2898301C (en) 2013-03-06 2021-11-16 Allergan, Inc. Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases
CN105007908B (zh) 2013-03-06 2017-10-03 阿勒根公司 用于治疗皮肤病的甲酰基肽受体2的激动剂的用途
EP3022188B1 (en) 2013-07-18 2017-06-07 Actelion Pharmaceuticals Ltd Piperazine substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx

Also Published As

Publication number Publication date
AU2014292064A1 (en) 2016-03-03
MX2016000731A (es) 2016-04-13
BR112016001106A2 (ru) 2017-07-25
US9533964B2 (en) 2017-01-03
EP3022188B1 (en) 2017-06-07
BR112016001106A8 (pt) 2017-12-26
CN105377824B (zh) 2017-08-04
EP3022188A1 (en) 2016-05-25
KR20160033747A (ko) 2016-03-28
TW201536289A (zh) 2015-10-01
JP6330038B2 (ja) 2018-05-23
AU2014292064B2 (en) 2018-07-05
MX360699B (es) 2018-11-14
US20160152584A1 (en) 2016-06-02
CA2915757A1 (en) 2015-01-22
JP2016525107A (ja) 2016-08-22
ES2639798T3 (es) 2017-10-30
WO2015007830A1 (en) 2015-01-22
CN105377824A (zh) 2016-03-02

Similar Documents

Publication Publication Date Title
RU2016105310A (ru) Пиперазин-замещенные мостиковые производные спиро[2.4]гептана в качестве агонистов alx рецептора
ES2683355T3 (es) Profármacos de fumaratos y su uso en el tratamiento de diversas enfermedades
MY167423A (en) Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators,compositions,and their use
EA201800064A1 (ru) 1,1,1-трифтор-3-гидроксипропан-2-ил карбаматные производные и 1,1,1-трифтор-4-гидроксибутан-2-ил карбаматные производные в качестве ингибиторов magl
HRP20171848T1 (hr) Upotreba malononitrilamida za neuropatsku bol
JP2005538099A5 (ru)
JP2013512903A5 (ru)
RU2006130000A (ru) Органические соединения
RU2013130878A (ru) Гидроксилированные производные аминотриазола в качестве агонистов рецептора alx
JP2016517857A5 (ru)
EA201650029A1 (ru) Пиразолопиридины и пиразолопиримидины
AR067326A1 (es) Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido
HRP20211278T1 (hr) Supstituirani derivati indolina kao inhibitori replikacije denga virusa
RU2016102059A (ru) Дифторэтил-оксазол замещенные мостиковые производные спиро-[2,4] гептана в качестве агонистов alх рецептора
EA201992162A1 (ru) Составы на основе нирапариба
HRP20202051T1 (hr) Aril supstituirani pirimidini za uporabu kod infekcije virusom influence
RU2014106611A (ru) Производные гетероциклических амидов в качестве антагонистов р2х7 рецептора
RU2015126015A (ru) Новые улавливатели в лечении макулодистрофии
JP2015522018A5 (ru)
RU2013130879A (ru) Производные оксазолилметилового эфира в качестве агонистов рецептора alx
PH12019500597A1 (en) CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE
JP2017525721A (ja) 認知欠損または認知障害に伴って進行する神経障害のおよび神経変性疾患の処置および予防のための製品
HRP20191869T1 (hr) Fluoroindol derivati kao pozitivni alosterički modulatori muskarinskog m1 receptora
EA202190586A1 (ru) N-замещенные диоксоциклобутениламино-3-гидроксипиколинамиды, приемлемые в качестве ингибиторов ccr6
RU2019111873A (ru) Новые антимикробные соединения, их применение для лечения инфекций млекопитающих и новый метаболический механизм